Meixin Health and AstraZeneca reached a strategic cooperation in the field of cardiovascular disease and launched the first long-term welfare guarantee plan

On April 23, Wuxi, Jiangsu, at the 2021 Taihu Bay Life and Health Future Conference, a major contract to solve the pain points of domestic chronic disease management was landed.

Shanghai Meixin Health Technology Co.

As the highlight of this strategic cooperation, the "Heart Sharing Future Drug Benefit Guarantee Plan" will also be launched in the near future.

"Private Order" for 330 million patients with cardiovascular disease

The "Heart Enjoy Future Drug Benefit Guarantee Plan" prepares two sets of insurance plans for patients, one for 3 years and the other for 5 years.

In addition to the main item of drug benefits, patients can also enjoy the complication insurance designed by Meixin Health separately for the project-during the enrollment period, if an acute myocardial infarction occurs, the patient can receive insurance compensation of up to 4,000 yuan.

"The'Heart Sharing Future Drug Benefit Guarantee Plan' is the first long-term cardiovascular disease protection program under Magnesium Health.

Solving the compliance problem of chronic disease management

Founded in 2017, Meixin Health is one of the few innovative medical payment service providers in China.

In the past, Meixin Health's business was mainly in the field of specialty drugs, mostly high-priced innovative oncology drugs.

Compared with the past business model, the "Heart Enjoy Future Drug Benefit Guarantee Plan" is a very important step in the business upgrade of Magnesium.

And this is exactly the pain point that the "Xingxiang Future Drug Benefit Guarantee Plan" wants to solve-the medication compliance of patients with chronic diseases.

"We have made a membership fee design.

△Feng Hao, general manager of Meixin Health Innovation Payment and Patient Services Division

In this regard, the project partner AstraZeneca agreed.

Obviously, this cooperation with Meixin Health is in line with AstraZeneca's long-term strategy.

Create an ecological closed loop of "Internet + medicine + medicine + insurance"

In the past four years of development of Meixin Health, "patient-centered" is the company's constant main line.

Zhang Xiaodong, CEO of Meixin Health, revealed to 8:00 Jianwen that the medical equipment company is one of the most important partners of Meixin Health.

On the other hand, Meixin Health has also continuously expanded its circle of friends in the insurance business, with the help of capital power to accelerate the formation of a closed payment loop.

In March of this year, Magnesium Health received 1 billion yuan of Series B financing jointly led by Ant Group, Shanghai Biopharmaceutical Industry Fund, and Innovation Works, and established a new goal of creating an ecological closed loop of "Internet + medicine + medicine + insurance".
Officially entered the unicorn sequence of medical payment services.
Only one year has passed since Magnesium’s last round of financing.
It is clear that the company’s development prospects have been recognized by cross-industry capital in the medical, commercial insurance and Internet fields.

"We have proven with actions and results that this is a path worth continuing to move forward.
" Zhang Xiaodong said that in the future, Magnesium Health will further closely integrate medical services, innovative drugs and commercial insurance, breaking through their original limitations and forming advantages.
Complementary, "Our goal is to bring more favorable prices and more convenient experience to patients.
We believe that this will ultimately contribute to a healthy China.
"